Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519532 | 0.90 | PTPN1 (0.47) | RAB9AMEN1KMT2ANOD1PTPN1 | |
| SCHEMBL7520917 | 0.88 | PTPN1 (0.42) | RAB9AMEN1KMT2ANOD1PTPN1 | |
| SCHEMBL7513085 | 0.87 | PTPN1 (0.47) | RAB9AKMT2APTPN1PTPN2PTPRC | |
| SCHEMBL7513118 | 0.85 | PTPN1 (0.41) | PTPN1PTPN2PTPRC | |
| SCHEMBL7519819 | 0.84 | RAB9A (0.44) | RAB9AMEN1KMT2ANOD1PTPN1 | |
| SCHEMBL7517024 | 0.84 | RAB9A (0.44) | RAB9AMEN1KMT2ANOD1PTPN1 | |
| SCHEMBL7522183 | 0.84 | PTPN1 (0.46) | RAB9AMEN1KMT2ANOD1PTPN1 | |
| SCHEMBL7520464 | 0.83 | PTPN1 (0.44) | RAB9AMEN1KMT2ANOD1PTPN1 | |
| SCHEMBL5837619 | 0.82 | PTPN1 (0.42) | PTPN1PTPN2PTPRC | |
| SCHEMBL7520327 | 0.81 | PTPN1 (0.43) | RAB9APTPN1PTPN2PTPRCNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | claimed |
| WO-2002004458-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-17 | — | — | WO | claimed |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | disclosed |
| WO-2002004458-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPN1, PTPRO, PTPRS | RAB9A 3157/4885MEN1 4795/4885KMT2A 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.